<b>Conclusions:</b> The apparent reduction in AD pathological protein tau/ptau and a neuroprotective proteomic profile in vivo suggest the potential for netarsudil to be developed as a new AD therapeutic agent. Here, MAPT is linked to Alzheimer disease.